Latest Articles
Latest
Expansion of IMBRUVICA® (ibrutinib) Label in the U.S.
U.S. Food and Drug Administration (FDA) Approves a Label Expansion for IMBRUVICA® (ibrutinib) On February 26th, Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced that the U.S. Food and Drug...
Into the world—Welcome Bexobrutideg!
Accelerate the Cure Into the world—Welcome Bexobrutideg!We recently wrote about a new type of drug—a BTK degrader— that emerged in 2024, for phase one trials at Nurix Therapeutics and BeOne. The Nurix trial earned FDA fast-track status in December. In a short three...
Thank You! The 2025 WM Giving Challenge.
Thank You for Helping Us Accelerate the Cure!A big thank-you to everyone in the IWMF community who supported Accelerate the Cure during our Global Challenge Research Tour! We had 1,291 people visit a research lab during the Tour. About 25% of them used our French,...
The Next Big Thing? Protein BTK Degraders
We are encouraged and excited to share ground-breaking news from Nurix Therapeutics, a pharmaceutical partner in WM-NET, our growing network of 22 US research institutions coordinating Waldenstrom's macroglobulinemia (WM) clinical trials, supported by Accelerate the...
VIDEO: Fitness Essentials for WM with Mark Wild
VIDEO NOW AVAILABLE!Exercise can feel overwhelming, especially with a cancer diagnosis. Symptoms like peripheral neuropathy and fatigue add to this challenge. Join Mark Wild, an award-winning cancer rehab expert and exercise coach. Learn about his thoughtful exercise...
2025 IWMF Ed Forum Speakers Announced
We’re excited to announce the great lineup of speakers for the 2025 Educational Forum! If you support the Accelerate the Cure Campaign, this is the event for you. Attending an IWMF Ed Forum shows IWMF's unique strength in building community while focusing on cancer...
Registration Now Open! The 2025 European Educational Forum
Join us for the 2025 European Educational Forum on Wednesday, May 21st, in Chantilly, France!We’re excited to partner with Waldenström France to bring you an exclusive opportunity to connect with over 80 world-leading experts in WM, thanks to our collaboration with...
Subscribe Today!
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean scelerisque suscipit condimentum. Vestibulum in scelerisque eros. Fusce sed massa vel sem commodo.
Featured Story
Lorem ipsum dolor sit consectetur adipiscing elit.
Proin eget tortor risus. Praesent sapien massa, convallis a pellentesque nec, egestas non nisi. Curabitur aliquet quam id dui posuere blandit. Curabitur arcu erat, accumsan id imperdiet et, porttitor at sem. Sed porttitor lectus nibh. Cras ultricies ligula sed magna dictum porta. Proin eget tortor risus. Curabitur non nulla sit amet nisl tempus convallis quis ac lectus. Nulla quis lorem ut libero malesuada feugiat.
Pellentesque in ipsum id orci porta dapibus. Nulla porttitor accumsan tincidunt. Nulla quis lorem ut libero malesuada feugiat. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; Donec velit neque, auctor sit amet aliquam vel, ullamcorper sit amet ligula. Vivamus suscipit tortor eget felis porttitor volutpat. Proin eget tortor risus. Cras ultricies ligula sed magna dictum porta. Proin eget tortor risus. Vivamus suscipit tortor eget felis porttitor volutpat.
Featured Author
Vestibulum Malesuada Non Magna Lacinia
Proin eget tortor risus. Praesent sapien massa, convallis a pellentesque nec, egestas no
Staff Picks
Expansion of IMBRUVICA® (ibrutinib) Label in the U.S.
U.S. Food and Drug Administration (FDA) Approves a Label Expansion for IMBRUVICA® (ibrutinib) On February 26th, Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced that the U.S. Food and Drug...
Into the world—Welcome Bexobrutideg!
Accelerate the Cure Into the world—Welcome Bexobrutideg!We recently wrote about a new type of drug—a BTK degrader— that emerged in 2024, for phase one trials at Nurix Therapeutics and BeOne. The Nurix trial earned FDA fast-track status in December. In a short three...
Expansion of IMBRUVICA® (ibrutinib) Label in the U.S.
U.S. Food and Drug Administration (FDA) Approves a Label Expansion for IMBRUVICA® (ibrutinib) On February 26th, Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced that the U.S. Food and Drug...
Into the world—Welcome Bexobrutideg!
Accelerate the Cure Into the world—Welcome Bexobrutideg!We recently wrote about a new type of drug—a BTK degrader— that emerged in 2024, for phase one trials at Nurix Therapeutics and BeOne. The Nurix trial earned FDA fast-track status in December. In a short three...
Thank You! The 2025 WM Giving Challenge.
Thank You for Helping Us Accelerate the Cure!A big thank-you to everyone in the IWMF community who supported Accelerate the Cure during our Global Challenge Research Tour! We had 1,291 people visit a research lab during the Tour. About 25% of them used our French,...
The Next Big Thing? Protein BTK Degraders
We are encouraged and excited to share ground-breaking news from Nurix Therapeutics, a pharmaceutical partner in WM-NET, our growing network of 22 US research institutions coordinating Waldenstrom's macroglobulinemia (WM) clinical trials, supported by Accelerate the...
VIDEO: Fitness Essentials for WM with Mark Wild
VIDEO NOW AVAILABLE!Exercise can feel overwhelming, especially with a cancer diagnosis. Symptoms like peripheral neuropathy and fatigue add to this challenge. Join Mark Wild, an award-winning cancer rehab expert and exercise coach. Learn about his thoughtful exercise...
Popular Categories
Categories
Gadgets & Devices
Fashion
Travel
Trending Now
Hot
Latest Trending
Featured Trending
Staff Picks
Expansion of IMBRUVICA® (ibrutinib) Label in the U.S.
U.S. Food and Drug Administration (FDA) Approves a Label Expansion for IMBRUVICA® (ibrutinib) On February 26th, Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced that the U.S. Food and Drug...
Into the world—Welcome Bexobrutideg!
Accelerate the Cure Into the world—Welcome Bexobrutideg!We recently wrote about a new type of drug—a BTK degrader— that emerged in 2024, for phase one trials at Nurix Therapeutics and BeOne. The Nurix trial earned FDA fast-track status in December. In a short three...
Expansion of IMBRUVICA® (ibrutinib) Label in the U.S.
U.S. Food and Drug Administration (FDA) Approves a Label Expansion for IMBRUVICA® (ibrutinib) On February 26th, Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced that the U.S. Food and Drug...
Into the world—Welcome Bexobrutideg!
Accelerate the Cure Into the world—Welcome Bexobrutideg!We recently wrote about a new type of drug—a BTK degrader— that emerged in 2024, for phase one trials at Nurix Therapeutics and BeOne. The Nurix trial earned FDA fast-track status in December. In a short three...
Expansion of IMBRUVICA® (ibrutinib) Label in the U.S.
U.S. Food and Drug Administration (FDA) Approves a Label Expansion for IMBRUVICA® (ibrutinib) On February 26th, Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced that the U.S. Food and Drug...
Into the world—Welcome Bexobrutideg!
Accelerate the Cure Into the world—Welcome Bexobrutideg!We recently wrote about a new type of drug—a BTK degrader— that emerged in 2024, for phase one trials at Nurix Therapeutics and BeOne. The Nurix trial earned FDA fast-track status in December. In a short three...
Vestibulum Malesuada Non Magna Lacinia
Home Office
Expansion of IMBRUVICA® (ibrutinib) Label in the U.S.
U.S. Food and Drug Administration (FDA) Approves a Label Expansion for IMBRUVICA® (ibrutinib) On February 26th, Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced that the U.S. Food and Drug...
Into the world—Welcome Bexobrutideg!
Accelerate the Cure Into the world—Welcome Bexobrutideg!We recently wrote about a new type of drug—a BTK degrader— that emerged in 2024, for phase one trials at Nurix Therapeutics and BeOne. The Nurix trial earned FDA fast-track status in December. In a short three...
Thank You! The 2025 WM Giving Challenge.
Thank You for Helping Us Accelerate the Cure!A big thank-you to everyone in the IWMF community who supported Accelerate the Cure during our Global Challenge Research Tour! We had 1,291 people visit a research lab during the Tour. About 25% of them used our French,...
The Next Big Thing? Protein BTK Degraders
We are encouraged and excited to share ground-breaking news from Nurix Therapeutics, a pharmaceutical partner in WM-NET, our growing network of 22 US research institutions coordinating Waldenstrom's macroglobulinemia (WM) clinical trials, supported by Accelerate the...
VIDEO: Fitness Essentials for WM with Mark Wild
VIDEO NOW AVAILABLE!Exercise can feel overwhelming, especially with a cancer diagnosis. Symptoms like peripheral neuropathy and fatigue add to this challenge. Join Mark Wild, an award-winning cancer rehab expert and exercise coach. Learn about his thoughtful exercise...
Our Recommended Products
Shop
